Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the treatment, but they regained control upon restarting it.

Juvenile idiopathic arthritis is the most common chronic systemic disease associated with uveitis in childhood. Uveitis occurs in 11–22% of children with juvenile idiopathic arthritis.1 Due to the ...

This case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, as well as highlights the unique ...

Patients with hidradenitis suppurativa experience knowledge gaps on effective treatments and addressing these gaps could help ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price ...

Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

Stock analysts at Wedbush lowered their Q4 2024 earnings estimates for Biogen in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biotechnology ...

and Biogen's Tysabri (natalizumab – both integrin inhibitors – as well as older branded and biosimilar TNF inhibitors including AbbVie's own blockbuster Humira (adalimumab). Meanwhile ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva ...

Crohn's disease and ulcerative colitis are idiopathic, chronic, relapsing, inflammatory conditions that are immunologically mediated. Although their exact etiologies remain uncertain, results from ...